- Poster presentation
- Open Access
Tissue characteristics and anatomic distribution of cardiac metastases among patients with advanced systemic cancer assessed by cardiac magnetic resonance (CMR)
© Pun et al. 2016
- Published: 27 January 2016
- Cardiac Magnetic Resonance
- Enhancement Pattern
- Cardiac Neoplasm
- Lymphatic Spread
- Tissue Characteristic
Cardiac metastases (CMET) impact management and clinical outcomes of patients with systemic neoplasms. CMR is well validated for evaluation of cardiac masses and increasingly used to assess oncologic patients, among whom pattern, tissue characteristics, and optimal diagnostic strategies for CMET are not known.
The population comprised consecutive adults (≥18 yo) with metastatic systemic neoplasms who underwent contrast-enhanced CMR between 1/2012 - 8/2015. Patients with primary cardiac neoplasms were excluded. CMR was performed using 1.5T (88%) and 3T (12%) clinical (GE) scanners. A standard contrast-enhanced CMR protocol was applied: Cine-CMR (SSFP) was used to assess cardiac structure and morphology. DE-CMR (IR-GRE, TI 250-350 msec, 0.2 mmol/kg gadolinium) was used for tissue characterization; long TI (600 msec) DE-CMR was employed to confirm tissue properties of visualized masses. CMET was defined using established criteria as a discrete, irregularly contoured mass with discrete borders independent of cardiac chambers, myocardium, or central catheters. CMET was further categorized based on enhancement pattern (absent, diffuse, heterogeneous enhancement with patchy hypoenhancement). Transthoracic echocardiography (echo), if performed clinically within 30 days of CMR, was used to test conventional imaging for CMET.
Diagnostic Performance of Transthoracic Echo for CMET as Established by CMR
Positive Predictive Value
Negative Predictive Value
CMET vary in location and enhancement pattern on CMR, often presenting without typical adjunctive findings such as pericardial or pleural effusions. Conventional screening via echo can be limited for CMET detection; incremental utility of CMR is typically provided for neoplasms that are intramyocardial or atypical in location.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.